Business Context and Reporting Period
This Form 8-K Current Report, dated April 15, 2024, pertains to CareDx, Inc. (CDNA), a Delaware corporation. The filing primarily addresses Item 5.02 regarding the appointment of new executive leadership and Item 8.01 regarding other events, specifically the issuance of a press release on April 16, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
The primary material change reported is the appointment of John W. Hanna as President and Chief Executive Officer (CEO) and a Class III director, effective April 15, 2024. Concurrently, the Company dissolved its Office of the Chief Executive Officer. The former members of that office will assume the following roles:
- Michael D. Goldberg: Chairperson of the Board
- Abhishek Jain: Chief Financial Officer
- Alexander L. Johnson: President of Patient & Testing Services
Compensation, Outlook, and Risks
Compensation Arrangements: Mr. Hanna's employment is "at will." His initial annualized salary is $675,000, with eligibility for an annual performance bonus of up to 100% of base salary. He received two inducement equity awards, each valued at $4,000,000:
- Inducement Option: Vests over four years (25% cliff after one year, then monthly).
- Inducement RSUs: Vest in four equal annual installments starting one year after the effective date.
Severance and Change of Control: A Change of Control and Severance Agreement provides for significant payouts if Mr. Hanna is terminated without Cause or resigns for Good Reason:
- During Change of Control Period: 18 months of base salary, 150% of target bonus, 100% acceleration of unvested equity, and 18 months of COBRA reimbursement.
- Outside Change of Control Period: 12 months of base salary, 12 months of COBRA reimbursement, and pro-rata vesting of initial equity tranches if terminated within the first year.
Risks and Contingencies: Mr. Hanna has entered into a Confidential Information, Invention Assignment, Non-Competition, and Arbitration Agreement (CIIA). This includes indefinite confidentiality, non-compete covenants during employment, non-solicit covenants for 12 months post-employment, and mandatory arbitration for employment disputes.
Investor Verification Checklist
- Verify the total dilution impact of the $8,000,000 in equity awards granted to Mr. Hanna.
- Review the full text of the Change of Control and Severance Agreement (Exhibit 10.2) to understand specific definitions of "Cause" and "Good Reason."
- Confirm the transition plan for the dissolved Office of the Chief Executive Officer and the new reporting structure.
- Assess the potential cash outflow implications of the severance package in the event of a change of control.